I

Inherent Targeting

3 employees

Inherent Targeting develops fluorescent contrast agents that target nerves to improve surgical outcomes.

Basic info

biotechnology

Medical Device

Medical

Health Care

2019

I

Inherent Targeting raised undisclosed on December 1, 2021

Investors: SciFounders